

<b>Author, year of publication, reference</b>	<b>Number of patients in metastatic setting</b>	<b>Study design</b>	<b>Study period</b>
Wang Y, 2017 (5)	FF: 55 GN: 66 G: 33	Retrospective	2014-2016
Kang J, 2018 (6)	FF: 159 GN: 149	Retrospective	2013-2016
Kim S, 2018 (8)	FF: 317 GN: 337	Retrospective Multicentric	2015
Cartwright TH, 2018	FF: 159 GN: 255 G: 72	Retrospective	2013-2015

**Supplementary Table 1**

<b>Progression-free survival (PFS)</b>	<b>Overall survival (OS)</b>	<b>Conclusion about Superiority of FF or GN in metastatic setting</b>
6.6 months	9.4 months	N/A
8.3 months	10.0 months	
3.1 months	3.6 months	
FF: 5.1 months	9.6 months	GN for OS (p=0.002)
GN: 6.8 months (NS)	11.4 months	
N/A	13.8 months	No superiority
N/A	12.1 months	
	(p=0.96)	
TTP: 4.3 months	11.4 months	No superiority
TTP: 3.7 months	9.8 months	
(p=0.25)	(p=0.38)	